Education
About Us
Working with TipRanks
Follow Us
NeuroOne Medical Technologies (NMTC)
NASDAQ:NMTC
NMTC Stock Chart & Stats
$0.78
-$0.09(-8.05%)
At close: 4:00 PM EST
$0.78
-$0.09(-8.05%)
Day’s Range― - ―
52-Week Range$0.40 - $1.16
Previous CloseN/A
Volume212.44K
Average Volume (3M)532.45K
Market Cap
$39.54M
Enterprise Value$36.22M
Total Cash (Recent Filing)$3.56M
Total Debt (Recent Filing)$237.38K
Price to Earnings (P/E)―
Beta1.48
Next Earnings
May 07, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding50,693,016
10 Day Avg. Volume702,340
30 Day Avg. Volume532,447
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)5.04
Price to Sales (P/S)2.95
P/FCF Ratio-12.22
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue4.16
Enterprise Value/Gross Profit7.57
Enterprise Value/Ebitda-5.31
Forecast
1Y Price Target
$2.25Price Target Upside188.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.14
Revenue Forecast (FY)$11.37M
Bulls Say, Bears Say
Bulls Say
Commercial AdoptionSupport from a major distribution partner and a rising share of procedures using the OneRF system indicate strengthening physician adoption and broader commercialization momentum.
Pipeline And PartnershipsPositive in-animal results for the spinal cord stimulation platform and advanced discussions with potential strategic partners could enable first-in-human testing and open new collaboration-driven revenue streams.
Technology AdvantageNeuroOne's thin, high-definition electrodes reduce brain trauma and enable combined diagnostic recording and therapeutic ablation in a single procedure, which could drive clinician preference over traditional electrodes.
Bears Say
Profitability RiskPersistent net losses create an ongoing profitability risk that may pressure investor sentiment and long-term valuation.
Revenue VariabilitySales can be uneven because partner stocking orders create lumpy demand, increasing short-term revenue volatility and forecasting difficulty.
Rising Operating ExpensesHigher expected operating expenses and wider GAAP loss-per-share estimates for fiscal years 2026 and 2027 could heighten dilution risk and weigh on near-term earnings expectations.
NeuroOne Medical Technologies News
NMTC FAQ
What was NeuroOne Medical Technologies’s price range in the past 12 months?
NeuroOne Medical Technologies lowest stock price was $0.40 and its highest was $1.16 in the past 12 months.
What is NeuroOne Medical Technologies’s market cap?
NeuroOne Medical Technologies’s market cap is $39.54M.
When is NeuroOne Medical Technologies’s upcoming earnings report date?
NeuroOne Medical Technologies’s upcoming earnings report date is May 07, 2026 which is in 44 days.
How were NeuroOne Medical Technologies’s earnings last quarter?
NeuroOne Medical Technologies released its earnings results on Feb 17, 2026. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.04 by $0.01.
Is NeuroOne Medical Technologies overvalued?
According to Wall Street analysts NeuroOne Medical Technologies’s price is currently Undervalued.
Does NeuroOne Medical Technologies pay dividends?
NeuroOne Medical Technologies does not currently pay dividends.
What is NeuroOne Medical Technologies’s EPS estimate?
NeuroOne Medical Technologies’s EPS estimate is -0.04.
How many shares outstanding does NeuroOne Medical Technologies have?
NeuroOne Medical Technologies has 50,693,016 shares outstanding.
What happened to NeuroOne Medical Technologies’s price movement after its last earnings report?
NeuroOne Medical Technologies reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.04. Following the earnings report the stock price went down -16.482%.
Which hedge fund is a major shareholder of NeuroOne Medical Technologies?
Currently, no hedge funds are holding shares in NMTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeuroOne Medical Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.25 (188.46% Upside)
$2.25 (188.46% Upside)
Insider Transactions
Bought Shares
Worth $658.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 12.7%
Last 30 Days ▲ 12.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.29%
12-Months-Change
Fundamentals
Return on Equity
-91.34%
Trailing 12-Months
Asset Growth
120.24%
Trailing 12-Months
Company Description
NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.
NMTC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced/Neutral — The call highlighted multiple operational and clinical achievements (accelerated programs, regulatory clearance, strong early clinical outcomes, product adoption, and meaningful fiscal 2026 revenue guidance of at least $10.5M). However, these positives are offset by near-term financial headwinds including a year-over-year revenue decline driven by the absence of prior license revenue, a drop in gross margin, a swing to a net loss, and a substantial reduction in cash on hand with funding only assured through fiscal 2026 unless milestones are met. The company shows promising commercial and development momentum but faces tangible liquidity and margin pressures that moderate the overall outlook.View all NMTC earnings summariesNMTC Stock 12 Month Forecast
Average Price Target
$2.25
▲(188.46% Upside)
Technical Analysis
Sensus Healthcare
―
Electrocore
―
Modular Medical
―
Vicarious Surgical
―
Inspira Technologies Oxy BHN
―
Ownership Overview
6.55% Insiders
3.38% Mutual Funds
17.37% Other Institutional Investors
69.95% Public Companies and
Individual Investors